gene

DES

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DES: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

190Connections
30Hypotheses
0Analyses
50Outgoing
50Incoming
18Experiments
0Debates

Summary

DES is a gene implicated in neurodegeneration research. Key relationships include: activates, implicated in, associated with. Associated with ALS, Aging, Als. Connected to 115 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info
Gene SymbolDES
Full NameDesmin
Chromosome2q35
Functionis a critical structural component of muscle cells[@paulin2004].
Molecular Weight53 kDa
Amino Acids470 aa
PathwaysAngiogenesis, Apoptosis, Autophagy, Ferroptosis, Necroptosis
UniProt IDP17661
NCBI Gene ID1674
Ensembl IDENSG00000175084
OMIM125660
GeneCardsDES
Human Protein AtlasDES
N-terminal head domain (residues 1-99)Contains phosphorylation sites and regulates filament assembly
Central rod domain (residues 100-411)Consists of four alpha-helical segments (1A, 1B, 2A, 2B) separated by linkers, responsible for dimerization and filament assembly
Associated DiseasesAging, Als, Alzheimer, Cancer, Cardiac, Cardiovascular
InteractionsAGING, AMPK, AND, APOPTOSIS, App, AUTOPHAGY
KG Connections190 knowledge graph edges
DatabasesGeneCardsHPASTRING
🔮 Predicted Structure: DES — AlphaFold P17661 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

DES Gene

gene · 1159 words

DES Protein

protein · 630 words

Pathway Diagram

graph TD
    DES["DES"]
    SMOC2["SMOC2"]
    DES -->|"co expressed with"| SMOC2
    DSP["DSP"]
    DES -->|"co expressed with"| DSP
    GJA1["GJA1"]
    DES -->|"co expressed with"| GJA1
    myofibrillar_myopathy{"myofibrillar myopathy"}
    DES -->|"causes"| myofibrillar_myopathy
    Aging{"Aging"}
    DES -->|"activates"| Aging
    Ms{"Ms"}
    DES -->|"activates"| Ms
    Cancer{"Cancer"}
    DES -->|"associated with"| Cancer
    Als{"Als"}
    DES -->|"therapeutic target"| Als
    DES -->|"therapeutic target"| Aging
    Tumor{"Tumor"}
    DES -->|"therapeutic target"| Tumor
    Longevity{"Longevity"}
    DES -->|"therapeutic target"| Longevity
    DES -->|"associated with"| Ms
    MCU["MCU"]
    MCU -->|"activates"| DES
    SLC7A11["SLC7A11"]
    SLC7A11 -->|"activates"| DES
    BECN1["BECN1"]
    BECN1 -->|"activates"| DES
    GENES["GENES"]
    GENES -->|"therapeutic target"| DES
    AMPK["AMPK"]
    AMPK -->|"activates"| DES
    ABCB1["ABCB1"]
    ABCB1 -->|"associated with"| DES
    FAS["FAS"]
    FAS -->|"interacts with"| DES
    CASP8["CASP8"]
    CASP8 -->|"interacts with"| DES
    CASP6["CASP6"]
    CASP6 -->|"interacts with"| DES
    MITOCHONDRIAL_DYSFUNCTION["MITOCHONDRIAL DYSFUNCTION"]
    MITOCHONDRIAL_DYSFUNCTION -->|"activates"| DES
    APOPTOSIS["APOPTOSIS"]
    APOPTOSIS -->|"activates"| DES
    CANCER["CANCER"]
    CANCER -->|"associated with"| DES
    style DES fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (138)

TargetRelationTypeStr
Myofibrillar Myopathycausesdisease0.95
GJA1co_expressed_withgene0.80
DSPco_expressed_withgene0.80
SMOC2co_expressed_withgene0.80
Alsactivatesdisease0.75

Incoming (52)

SourceRelationTypeStr
MCUactivatesgene0.60
SLC7A11activatesgene0.60
BECN1activatesgene0.60
ABCB1associated_withgene0.60
VEGFtherapeutic_targetgene0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Exposed amyloidogenic segments (β-sheet propensity residues) 0.840 protein-biochemistry Do chaperones selectively recognize path
J-protein substrate specificity codes enable HSP70 discrimin 0.840 protein-biochemistry Do chaperones selectively recognize path
TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects S 0.813 synaptic-biology Does SPP1-mediated synaptic engulfment r
Competitive APOE4 Domain Stabilization Peptides 0.784 neurodegeneration APOE4 structural biology and therapeutic
Tau dysfunction destabilizes labile pool 0.750 neurodegeneration -
Circulating Soluble PDGFRβ Reflects Pericyte Loss and Preced 0.745 - What blood-brain barrier permeability ch
Metabolic Inflexibility Precedes Transcriptional Reprogrammi 0.735 neurodegeneration What is the optimal therapeutic window f
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides 0.718 neurodegeneration Blood-brain barrier transport mechanisms
NRF2 Activation Provides Neuroprotection Across ALS, AD, and 0.710 neurodegeneration Test Preregistration Analysis
H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properti 0.698 neurodegeneration How do pathological stress granules tran
Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurode 0.690 neurodegeneration Gap 006 analysis (archived stub)
Vascular mural cell degeneration precedes and exacerbates pa 0.661 alzheimers SEA-AD Single-Cell Analysis: Cell-Type V
ATXN2 Antisense Oligonucleotides Reduce Dipeptide Repeat Pro 0.630 neurodegeneration Test
Circulating Soluble PDGFRβ Reflects Pericyte Loss and Preced 0.625 - What blood-brain barrier permeability ch
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m 0.621 neurodegeneration Mitochondrial transfer between astrocyte
DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against T 0.604 neurodegeneration Should microtubule-stabilizing drugs be
whether the Mitochondrial transfer between neurons and glia 0.604 neurodegeneration Methodology challenge: notebook 'Mitocho
whether the Astrocyte reactivity subtypes in neurodegenerati 0.604 neurodegeneration Methodology challenge: notebook 'Astrocy
whether the Mitochondrial transfer between neurons and glia 0.604 neurodegeneration Methodology challenge: notebook 'Mitocho
Stratified falsifiers should govern Methodology challenge: n 0.591 neurodegeneration Methodology challenge: notebook 'Astrocy
Stratified falsifiers should govern Methodology challenge: n 0.591 neurodegeneration Methodology challenge: notebook 'Mitocho
Stratified falsifiers should govern Methodology challenge: n 0.591 neurodegeneration Methodology challenge: notebook 'Mitocho
Closed-Loop Phase-Specific Targeting of PV-to-Pyramidal Syna 0.585 alzheimers Closed-loop optogenetic targeting PV int
TREM2-Driven Phagocytic Receptor Cascades Determine Mitochon 0.580 neurodegeneration What determines organelle-specific autop
Astrocyte cGAS/STING Activation Converts Protective into Des 0.580 neuroinflammation How does chronic cGAS/STING activation d
LYTL and JIP4-dependent lysosomal remodeling may show mutant 0.580 neurodegeneration Do pathogenic LRRK2 mutations amplify vo
NAD+/SARM1 Axis Provides Metabolic Feedback Coupling Mitopha 0.578 neurodegeneration How do different organelle-specific auto
Post-Translational Modification Codes Determine Interaction 0.560 neurodegeneration What determines the specificity of RNA-p
CX3CR1-Targeted AntimiR-155 Oligonucleotides for Microglial 0.530 pharmacology How can CNS-selective HDAC/DNMT inhibito
Closed-loop transcranial focused ultrasound to restore hippo 0.000 alzheimers Circuit-level neural dynamics in neurode

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (18)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
GWAS of plasma NfL in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma pTau217 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
Dairy intake and dementia risk in Malmö Diet and Cancer cohort clinical Alzheimer's disease 0.950 0.00 Swedish community-based adults proposed N/A
GWAS of plasma pTau181 in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
GWAS of plasma GFAP in East Asian cohort exploratory Alzheimer's disease 0.950 0.00 human patients - East Asian co proposed N/A
KEEPS Continuation: Long-term effects of menopausal hormone therapy on clinical Alzheimer's disease 0.950 0.00 recently menopausal women with proposed N/A
GWAS of composite biomarker score exploratory Alzheimer's disease 0.900 0.00 human patients - East Asian co proposed N/A
RBG treatment in ApoE-/- atherosclerosis mouse model validation atherosclerosis 0.900 0.00 ApoE-/- mice proposed N/A
APOE4 association with TDP-43 pathology in AD exploratory Alzheimer's disease 0.750 0.00 human patients proposed N/A
s:** - Biochemical binding assays measuring PROTAC selectivity for APO falsification Neurodegeneration 0.400 0.50 cell_line proposed $100,000
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv clinical Alzheimer's Disease 0.400 0.50 human proposed $6,550,000
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau clinical Alzheimer's Disease 0.400 0.50 cell_line proposed $180,000
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig clinical Alzheimer's Disease 0.400 0.50 human proposed $7,100,000
ApoE4 Function in Alzheimer's Disease validation Alzheimer's Disease 0.400 0.50 mouse proposed $360,000
Blood-Based Biomarker Panel for Early AD Detection clinical Alzheimer's Disease 0.400 0.50 cell_line proposed $220,000
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeutic Timing clinical Alzheimer's Disease 0.400 0.50 human proposed $7,500,000
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease validation Alzheimer's Disease 0.400 0.50 human proposed $2,730,000
Sex Differences in Alzheimer's Disease — mechanisms and therapeutic im clinical Alzheimer's Disease 0.400 0.50 human proposed $7,500,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] Litvinchuk A, Suh JH, Guo JL, Lin K, Dav Neuron 2024 1
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] Maxine R Nelson, Peng Liu, Ayushi Agrawa Nature neuroscience 2023 1
Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmon [PMID:35257044] Calvier L, Herz J, Hansmann G JACC Basic Transl Sci 2022 1
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. [PMID:36348357] Raulin AC, Doss SV, Trottier ZA, Ikezu T Mol Neurodegener 2022 1
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] Serrano-Pozo A, Das S, Hyman BT Lancet Neurol 2021 1
Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] Banik SM, Pedram K, Wisnovsky S, Ahn G, Nature 2020 1
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] Long JM, Holtzman DM Cell 2019 1
Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventin [PMID:30595089] Brophy ML, Dong Y, Tao H, Yancey PG, Son Circ Res 2019 1
Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical [PMID:28381441] Shinohara M, Tachibana M, Kanekiyo T, Bu J Lipid Res 2017 1
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] Cetindag AC, Schipke CG, Esselmann H, Kr The journal of prevention of A 2026 0
Modulation of apolipoprotein E receptor-2 by ApoE4, amyloid β-peptide, reelin, a [PMID:41858499] ["Barger S", "Moerman-Herzog A"] Frontiers in molecular neurosc 2026 0
ASS1 Promotes Atherosclerotic Inflammation Through the NLRP3/IL-33/ST2 Axis in O [PMID:41914296] Wu S, Han F, Qiao Z, Yuan S, Bian X, Zha Frontiers in bioscience (Landm 2026 0
CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] ["Wang M", "Niu D", "Zhang Q", "Tang Y", International journal of biolo 2026 0
Multimodal biomarker AI techniques for early neurocognitive disorder diagnosis: [PMID:41921464] Catino F, Castellana F, Zupo R, Giannocc Artificial intelligence in med 2026 0
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] Thedim M, Hu J, Maher M, Wiener-Kronish Br J Anaesth 2026 0
Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] Bae H, Song Z, Ali A, Sasaki T, Tesi N e Geroscience 2026 0
Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] Stern A, Linial M Geroscience 2026 0
Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] Samudra N, Vemuri M, Weitlauf J Curr Opin Obstet Gynecol 2026 0
Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who a [PMID:41689888] Perry R, Kipps C, Soto Martín ME, Bozzal J Prev Alzheimers Dis 2026 0
Hepatocyte-Specific Knockout of YAP Protects Against Atherosclerosis via Inhibit [PMID:41744066] Hou Y, Zhang X, Sun X, Qin Q, Jia M et a Arterioscler Thromb Vasc Biol 2026 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning DES in their description or question text

Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline

Score: 0.745 · unknown disease · 2026-04-26

Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blo

Metabolic Inflexibility Precedes Transcriptional Reprogramming (NAD+/SIRT3 Axis)

Score: 0.735 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The NAD+/SIRT3 axis represents a critical regulatory hub controlling mitochondria

Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides

Score: 0.718 · neurodegeneration · 2026-04-02

## Mechanistic Overview Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides starts from the claim that modulating

NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD

Score: 0.710 · neurodegeneration · 2026-04-28

Genetic or pharmacologic NRF2 activation using CDDO-EA or sulforaphane upregulates ARE gene transcription (NQO1, HO-1, G

H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properties

Score: 0.698 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The pathogenic mechanism underlying C9orf72-associated amyotrophic lateral sclero

Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurodegeneration in FTD-GR

Score: 0.690 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The pathogenesis of frontotemporal dementia with GRN mutations (FTD-GRN) involves

Vascular mural cell degeneration precedes and exacerbates parenchymal pathology

Score: 0.661 · alzheimers · 2026-04-04

## Mechanistic Overview Vascular mural cell degeneration precedes and exacerbates parenchymal pathology starts from the

ATXN2 Antisense Oligonucleotides Reduce Dipeptide Repeat Proteins in C9orf72-ALS

Score: 0.630 · neurodegeneration · 2026-05-10

ASO-mediated knockdown of ATXN2 reduces repeat-associated non-AUG translation of toxic dipeptide repeat proteins from C9

Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline

Score: 0.625 · unknown disease · 2026-04-26

Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blo

Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial deliver

Score: 0.621 · neurodegeneration · 2026-04-02

## Mechanistic Overview Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery starts from th

DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabili

Score: 0.604 · neurodegeneration · 2026-04-15

## Mechanistic Overview DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabilization starts fr

whether the Mitochondrial transfer between neurons and glia — Rich Analysis Note

Score: 0.604 · neurodegeneration · 2026-04-28

The debate supports carrying forward whether the Mitochondrial transfer between neurons and glia — Rich Analysis Noteboo

whether the Astrocyte reactivity subtypes in neurodegeneration — Rich Analysis N

Score: 0.604 · neurodegeneration · 2026-04-28

The debate supports carrying forward whether the Astrocyte reactivity subtypes in neurodegeneration — Rich Analysis Note

whether the Mitochondrial transfer between neurons and glia — Rich Analysis Note

Score: 0.604 · neurodegeneration · 2026-04-28

The debate supports carrying forward whether the Mitochondrial transfer between neurons and glia — Rich Analysis Noteboo

Stratified falsifiers should govern Methodology challenge: notebook 'Astrocyte r

Score: 0.591 · neurodegeneration · 2026-04-28

Claims from this analysis should be evaluated across Methodology, challenge, Astrocyte, reactivity, subtypes, neurodegen